FSA Wealth Management LLC Takes Position in Zoetis Inc. (NYSE:ZTS)

FSA Wealth Management LLC acquired a new position in shares of Zoetis Inc. (NYSE:ZTS) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 427 shares of the company’s stock, valued at approximately $83,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in ZTS. Darwin Wealth Management LLC acquired a new stake in Zoetis in the third quarter worth $31,000. First Personal Financial Services bought a new position in Zoetis during the third quarter worth about $33,000. Capital Performance Advisors LLP acquired a new position in Zoetis in the third quarter valued at about $33,000. Quarry LP increased its holdings in shares of Zoetis by 273.2% in the second quarter. Quarry LP now owns 209 shares of the company’s stock worth $36,000 after acquiring an additional 153 shares in the last quarter. Finally, Fortitude Family Office LLC increased its holdings in shares of Zoetis by 1,387.5% in the third quarter. Fortitude Family Office LLC now owns 238 shares of the company’s stock worth $46,000 after acquiring an additional 222 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Down 0.8 %

Shares of ZTS stock opened at $175.25 on Monday. The firm’s fifty day moving average price is $183.83 and its two-hundred day moving average price is $180.97. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $201.92. The firm has a market capitalization of $79.07 billion, a P/E ratio of 32.94, a PEG ratio of 2.69 and a beta of 0.89.

Zoetis (NYSE:ZTS) last released its earnings results on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The business had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.29 billion. During the same quarter in the previous year, the business earned $1.36 earnings per share. Zoetis’s quarterly revenue was up 11.6% on a year-over-year basis. On average, equities analysts predict that Zoetis Inc. will post 5.9 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 3rd. Stockholders of record on Thursday, October 31st will be issued a $0.432 dividend. This represents a $1.73 annualized dividend and a dividend yield of 0.99%. The ex-dividend date of this dividend is Thursday, October 31st. Zoetis’s payout ratio is presently 32.52%.

Analyst Ratings Changes

Several equities analysts have recently weighed in on ZTS shares. BTIG Research lifted their price objective on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a report on Monday, August 12th. JPMorgan Chase & Co. lifted their price target on shares of Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. Argus raised shares of Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. Stifel Nicolaus boosted their price objective on shares of Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research report on Wednesday, September 18th. Finally, Piper Sandler increased their target price on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. Ten equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Zoetis has an average rating of “Buy” and a consensus target price of $221.44.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.